Cite
MLA Citation
Shashank Nigam et al.. “P081: Dual anti-HER-2 blockade with primary systemic therapy for HER-2 positive non-metastatic breast cancer can increase breast conservation rates: Benefit beyond survival.” European journal of surgical oncology, vol. 46, no. 6, 2020, pp. e32–. http://access.bl.uk/ark:/81055/vdc_100104363856.0x000031